This findingis particularly interesting because pharmacological activation of mGlu2/3 receptorscan also improve motor deficits in experimental models of parkinsonism [50],[51].The good profile of safety and tolerability of mGlu2/3 receptor agonists in clinicalstudies [34] may encourage the use of mGlu2/3 receptoragonists in the experimental treatment of Parkinson's disease. This evidence concerns the gene GRM2 and Parkinson disease.